DK0584136T3 - Bestemmelse af peptidmotiver på MHC-molekyler - Google Patents

Bestemmelse af peptidmotiver på MHC-molekyler

Info

Publication number
DK0584136T3
DK0584136T3 DK92909723T DK92909723T DK0584136T3 DK 0584136 T3 DK0584136 T3 DK 0584136T3 DK 92909723 T DK92909723 T DK 92909723T DK 92909723 T DK92909723 T DK 92909723T DK 0584136 T3 DK0584136 T3 DK 0584136T3
Authority
DK
Denmark
Prior art keywords
peptide motifs
pct
determination
date
mhc molecules
Prior art date
Application number
DK92909723T
Other languages
English (en)
Inventor
Olaf Ritzschke
Stefan Stevanovic
Hans-Georg Rammensee
Kirsten Falk
Guenther Jung
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19914116256 external-priority patent/DE4116256C2/de
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK0584136T3 publication Critical patent/DK0584136T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK92909723T 1991-05-17 1992-05-15 Bestemmelse af peptidmotiver på MHC-molekyler DK0584136T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19914116256 DE4116256C2 (de) 1991-05-17 1991-05-17 Bestimmung von Peptidmotiven auf MHC-Molekülen
PCT/EP1992/001072 WO1992021033A1 (de) 1991-05-17 1992-05-15 Bestimmung von peptidmotiven auf mhc-molekülen

Publications (1)

Publication Number Publication Date
DK0584136T3 true DK0584136T3 (da) 2000-05-22

Family

ID=6431930

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92909723T DK0584136T3 (da) 1991-05-17 1992-05-15 Bestemmelse af peptidmotiver på MHC-molekyler

Country Status (10)

Country Link
US (1) US5747269A (da)
EP (1) EP0584136B1 (da)
JP (2) JP3424752B2 (da)
AT (1) ATE189527T1 (da)
AU (1) AU1694392A (da)
CA (2) CA2103148C (da)
DE (2) DE4143467C2 (da)
DK (1) DK0584136T3 (da)
ES (1) ES2145007T3 (da)
WO (1) WO1992021033A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
DE4238416A1 (de) * 1992-11-13 1994-05-19 Max Planck Gesellschaft Bestimmung von Peptidmotiven auf MHC-Molekülen
DE4423392A1 (de) * 1994-07-04 1996-01-11 Birsner & Grob Biotech Gmbh Verfahren zur Identifizierung antigener Peptide
US6413517B1 (en) 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6379970B1 (en) * 1999-04-30 2002-04-30 The Arizona Board Of Regents On Behalf Of The University Of Arizona Analysis of differential protein expression
DE19925235A1 (de) 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
DE19925199A1 (de) * 1999-06-01 2000-12-07 Medigene Ag Zytotoxische T-Zellepitope des Papillomavirus L1-Proteins und ihre Verwendung in Diagnostik und Therapie
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
DK1230268T3 (da) 1999-11-18 2010-02-08 Epimmune Inc Heteroklitiske analoger af klasse I-epitoper
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
DE60142615D1 (de) * 2000-04-28 2010-09-02 Mannkind Corp Epitop-synchronisierung in antigen präsentierenden zellen
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN1313617C (zh) * 2001-11-07 2007-05-02 曼康公司 编码靶相关抗原表位的表达载体及其设计方法
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
EP2351576A1 (en) * 2004-12-29 2011-08-03 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
WO2006124408A2 (en) * 2005-05-12 2006-11-23 Merck & Co., Inc. System and method for automated selection of t-cell epitopes
US7964200B2 (en) 2005-05-18 2011-06-21 Children's Hospital & Research Center At Oakland Methods and compositions for immunizing against Chlamydia infection
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
ES2527412T3 (es) 2007-02-15 2015-01-23 Mannkind Corporation Método para aumentar la respuesta de los linfocitos T
WO2008148068A1 (en) * 2007-05-23 2008-12-04 Mannkind Corporation Multicistronic vectors and methods for their design
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0365525B1 (en) * 1987-01-30 1995-08-09 The Board Of Trustees Of The Leland Stanford Junior University Lymphocyte inhibition by hla peptides
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases

Also Published As

Publication number Publication date
WO1992021033A1 (de) 1992-11-26
DE4143467C2 (de) 1995-02-09
CA2103148A1 (en) 1992-11-18
ATE189527T1 (de) 2000-02-15
US5747269A (en) 1998-05-05
CA2471093A1 (en) 1992-11-26
JP2003176300A (ja) 2003-06-24
CA2103148C (en) 2004-07-20
DE59209810D1 (de) 2000-03-09
JPH06510850A (ja) 1994-12-01
JP3424752B2 (ja) 2003-07-07
EP0584136A1 (de) 1994-03-02
ES2145007T3 (es) 2000-07-01
AU1694392A (en) 1992-12-30
EP0584136B1 (de) 2000-02-02

Similar Documents

Publication Publication Date Title
DK0584136T3 (da) Bestemmelse af peptidmotiver på MHC-molekyler
DK0696297T3 (da) Pyridobisimidazolbaseret stiv stavpolymer
DK0669001T3 (da) Bestemmelse af peptidmotiver på MHC-molekyler
DK1200418T3 (da) Nematodicide trifluorbutener
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
ES2053907T3 (es) Pomada topica.
DE69225410D1 (de) Herstellung von n-acetylneuraminsäure-derivaten
HUT77631A (hu) Eljárás a levobupivakain és származékai rezolválására
DK0786004T3 (da) Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
DE69412073D1 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
DK0865271T4 (da) Anvendelse af 2-ethylhexyl alfa-cyano-beta, beta-diphenylacrylat med henblik på at forbedre stabiliteten over for lys af p-methylbenzyliden-kamfer
CS9100438A2 (en) New derivative of beta-phenylisoserine, method of its preparation and its application
ES2162078T3 (es) Compuestos terapeuticos.
DK0809627T3 (da) Hidtil ukendte borneolderivater, fremgangsmåde til deres fremstilling og deres farmaceutiske anvendelse
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
DE69323191T2 (de) Wasserlösliche retinoide
ES2123570T3 (es) Uso de la molecula de adhesion de leucocitos y endotelios 1 y anticuerpos contra ella en el tratamiento del asma.
ATE265418T1 (de) Neue substituierte 3-phenoxy- und 3- phenylalkyloxy-2-phenyl-propylamine
ATE221068T1 (de) Anellierte beta-carboline
DK0958290T3 (da) 1,4-Dihydropyridinderivater og terapeutisk anvendelse heraf
SE9501773D0 (sv) New use
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren